Monday, 9 December 2013

More from the ASCEPT conference



Ms Shiying Wu, a final year medical student about to graduate from Monash University Medical School, presented a poster and was invited to present an oral at the 2013 Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT). The topic was “Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: a meta-analysis of randomised clinical trials with 55,141 participants”. She collaborated with researchers from the Centre for Cardiovascular Research and Education in Therapeutics. 


The meta-analysis of 50 studies demonstrated that the oral hypoglycaemic agent used for the treatment of type 2 diabetes delivers neither cardiovascular benefit nor harm in major cardiovascular outcomes, however did suggest that there may be an increase in heart failure events. This finding will need to be confirmed in future large cardiovascular outcome trials. 

Co-authors Professor Henry Krum, Dr Ingrid Hopper and Mrs Marina Skiba praised Ms Wu for pursuing this research in the face of her heavy final year study commitments. “We have been highly impressed with Ms Wu’s time management and courage to persist with this research. She has a passion for pharmacology which we hope will continue to drive her research interests” commented Dr Hopper.  

“Research complements medical students’ training, and gives them a competitive edge.” added Professor Krum. “We are always happy to discuss research opportunities with medical students.”
Ms Wu will be returning to her native Singapore for her internship.

No comments:

Post a Comment

linkwithin

Related Posts Plugin for WordPress, Blogger...